BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Week In Review | Nov 16, 2018
Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
BC Extra | Nov 13, 2018
Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
BC Week In Review | Jan 19, 2018
Company News

PTAB denies Concert's challenge to Jakafi patent

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) said the U.S. Patent Trial and Appeal Board declined the company’s post grant review (PGR) petition challenging U.S. Patent No. 9,662,335, which covers Jakafi ruxolitinib from Incyte Corp. (NASDAQ:INCY). Concert said...
BC Extra | Jan 12, 2018
Company News

PTAB denies Concert's challenge to Jakafi patent

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $7.53 (27%) to $20.15 on Friday after the U.S. Patent Trial and Appeal Board declined the company’s post grant review (PGR) petition challenging U.S. Patent No. 9,662,335, which covers Jakafi...
BC Week In Review | Jul 21, 2017
Clinical News

FDA lifts hold on Phase IIa of Concert's CTP-543 in alopecia areata

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) said FDA lifted a hold on its double-blind, placebo-controlled, U.S. Phase IIa trial of twice-daily 4 and 8 mg oral CTP-543 to treat moderate to severe alopecia areata in about 90...
BC Week In Review | Jun 15, 2017
Clinical News

FDA places hold on Phase IIa of Concert's alopecia areata candidate

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) received notice that FDA placed a clinical hold on a Phase IIa trial of CTP-543 to treat moderate to severe alopecia areata. Concert said it had already started the trial with...
BC Week In Review | May 4, 2017
Clinical News

Concert begins Ph IIa of CTP-543 in alopecia areata

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) began a Phase IIa trial of CTP-543 to treat moderate to severe alopecia areata. The double-blind, U.S. trial will evaluate hair loss as measured by the Severity of Alopecia Tool (SALT)...
BC Extra | Mar 6, 2017
Company News

Concert rises after selling CF programs to Vertex

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) jumped $5.99 (62%) to $15.64 on Monday after it said Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) will acquire all of its cystic fibrosis programs, including CTP-656 , a deuterated version of Vertex's Kalydeco ivacaftor....
BC Week In Review | May 30, 2016
Clinical News

CTP-543: Phase I started

Concert began a double-blind, placebo-controlled, dose-escalation, Australian Phase I trial to evaluate single doses of oral CTP-543 and once- or twice-daily CTP-543 for 1 week in about 80 healthy volunteers. Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington,...
Items per page:
1 - 10 of 10